This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Cipro buyers oppose summary judgment in class action over $398.1 million reverse-payment

( July 8, 2016, 22:45 GMT | Official Statement) -- MLex Summary: Bayer paid $398.1 million to avoid the risk of the introduction of a generic version of the antibiotic Cipro, a payment that was clearly intended to avoid competiton in violation of California's antitrust law, plaintiffs suing over the alleged reverse-payment said. The defendants are relying on an incorrect legal standard to argue that plaintiffs haven't shown the payment caused the alleged delay, the plaintiffs said.See documents below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login